AC
ABCL icon

AXQ Capital’s AbCellera Biologics ABCL Stock Holding History

AXQ Capital’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$475K Buy
+136,227
New +$490K 0.06% 429
2023
Q4 		– Sell
-27,000
Closed -$124K – 621
2023
Q3 		$124K Buy
+27,000
New +$164K 0.04% 417

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $33.7B AUM 35.49% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

AXQ Capital's ABCL Position: Q1 2026 in Review

AXQ Capital opened a new position in AbCellera Biologics (ABCL) in Q1 2026: 136,227 shares worth $475K. The stake represents 0.06% of the portfolio and ranks #429 among its holdings. This is a return to the name: AXQ Capital previously reported a position in ABCL as recently as Q3 2023.

AXQ Capital first reported a position in ABCL in Q3 2023 and has held it in 2 quarters since. 138 funds tracked by Wall St. Rank hold ABCL as of Q1 2026.

  • AXQ Capital held 136,227 shares of AbCellera Biologics worth $475K as of Q1 2026.
  • AbCellera Biologics was a new AXQ Capital position in Q1 2026.
  • AbCellera Biologics made up 0.06% of AXQ Capital's portfolio in Q1 2026, its #429 holding.
  • AXQ Capital first reported a position in AbCellera Biologics in Q3 2023 and has held it in 2 quarters since.
  • 138 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2026.

Based on AXQ Capital's 13F filing for Q1 2026, filed 13 May 2026.